BridgeMD
New treatment option for Breast Cancer
Official title Cardiotoxicity in Breast Cancer Patients
ClinicalTrials.gov ID: NCT06491680
What this study is testing
What is Dapagliflozin 10mg Tab?
Dapagliflozin 10mg Tab is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for breast cancer.
Also referred to as Dapablix 10 mg.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
- Phase 4: studies an already-approved treatment
- Time commitment: about 7 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- patients with pathologically proved invasive breast carcinoma.
- Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines.
- Renal function (eGFR \> 30 mL/minute per 1.73 m2 )
- LVEF is more than 50 %
- Age ≥ 18 and ≤ 60 years old
You likely can't join if
- patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction.
- Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens
- pregnant or breastfeeding patients
- patients receiving any other cardiotoxic agents.
- Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.
- Mediastinal irradiation including heart.
See the full eligibility criteria
- patients with pathologically proved invasive breast carcinoma.
- Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines.
- Renal function (eGFR \> 30 mL/minute per 1.73 m2 )
- LVEF is more than 50 %
- Age ≥ 18 and ≤ 60 years old
- patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction.
- Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens
- pregnant or breastfeeding patients
- patients receiving any other cardiotoxic agents.
- Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.
- Mediastinal irradiation including heart.
- Refusal to sign the written informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Cairo Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 7 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Cairo Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.